standardization of paederia foetida extract for developing...
TRANSCRIPT
R&D PROJECT PROPOSAL
ON
STANDARDIZATION OF PAEDERIA FOETIDA EXTRACT
FOR DEVELOPING A HERBAL FORMULATION TO TREAT
PEPTIC ULCER
Principal Investigator
Dr. Kuldeep Singh
Co-Investigators
Mr. Udayabanu M.
Ms. Silpi Chanda
Jaypee University of Information Technology
Waknaghat, Solan-173215 (H.P.)
2
PROFORMA – I
PROFORMA FOR SUBMISSION OF PROJECT PROPOSALS ON RESEARCH AND
DEVELOPMENT, PROGRAMME SUPPORT
PART I: GENERAL INFORMATION
1. Name of the Institute/University/Organisation submitting the Project Proposal:
Department of Biotechnology , Bioinformatics & Pharmaceutical Sciences, Jaypee University of
Information Technology, Waknaghat, P.O. Dumehar Bani, Kandaghat, District Solan-173215
(H.P.) INDIA
2. State: Himachal Pradesh
3. Status of the Institute: State University
4. Name and designation of the Executive Authority of the Institute/University forwarding
the application: Dr. Ravi Prakash, Vice-Chancellor, Jaypee University of Information
Technology (HP)
5. Project Title: STANDARDIZATION OF PAEDERIA FOETIDA EXTRACT FOR
DEVELOPING A HERBAL FORMULATION TO TREAT PEPTIC ULCER
6. Category of the Project (Please tick): R&D Support
7. Specific Area: Aromatic and Medicinal Plant
8. Duration: 3 Years
9. Total Cost (Rs.): 47.128 lakhs + Overheads As applicable
10. Is the project Single Institutional or Multiple-Institutional (S/M)? : S
12. Scope of application indicating anticipated product and processes
1. Studies will result in the standardization, chemical modification and formulation of a
suitable herbal formulation for peptic ulcer.
2. Exploration of chemically engineered extracts would be a useful resource of chemical
library of natural products with potential applications.
3. The prepared herbal formulation will not only be a remedy for PUD patients but will also
target patients who regularly consume NSAIDs especially in case of arthritic and post
operative patients.
13. Project Summary
Paederia foetida Linn. (Rubiaceae), known as ‗Prasarini‘ in Sanskrit is an extensive foetid smell
climber. It has been used for various purposes in the Indian systems of medicine as well as in
folk-lore medicine (Table 2). The tribal community of Northeast part of India and other parts of
Asia including Bangladesh use this plant mainly for gastro intestinal diseases. Our aim is to find
out a most active standardized fractional extract which could be formulated for the treatment of
peptic ulcer disease (PUD). Chemical modification of the most active fraction will also be done
with an aim to increase the potency/efficacy of the extract.
3
The project emphasizes on the Indigenous System of Medicine, mainly the study of plants used
by the tribal people of North-Eastern region of India as a food as well as medicine. To the best
of our knowledge, no systematic study has been done in the field of standardization and
formulation of herbal preparation with the chemical modification.
The approach involves extraction of plant material with various solvents and their profiling for
anti-ulcer activity. We will use different models for this study (described later in this proposal).
Bio-guided fractionation will be used to identify active fractions. Plant extracts have synergistic
effects of various molecules present and our aim is to enrich them by bio-guided fractionation
method. We plan to obtain a biological fingerprint of each extract step by step through
pharmacological evaluation of their anti ulcer activity.
While we are in the search of active fractions, we would also do chemical modification of
natural molecules present in such fractions. We would employ a methodology —Chemically
Engineered Extracts (CEE) — for chemical diversification.1 Natural extracts like libraries will
be generated by using CEE method.
Expected outcome of this project is to obtain a standardized extract, to have enriched fraction
with chemical modification and formulation of that bioactive enriched fraction as herbal
formulation that could be used for peptic ulcer disease.
4
PART II: PARTICULARS OF INVESTIGATORS
14. Name Dr. Kuldeep Singh
Date of Birth 01/11/1978
Designation Senior Lecturer
Department Biotechnology, Bioinformatics and Pharmaceutical Sciences
Institute/University Jaypee University of Information Technology
Address Waknaghat, P.O. Dumehar Bani, Kandghat, District
Solan- (H.P.) INDIA, PIN: 173215
Telephone 01792-239391
Fax: 01792-245362 E-mail: [email protected]
Number of research projects being handled at present: None
Co-Investigators
15a. Name Mr. Udayabanu M.
Date of Birth 01/09/ 1977
Designation Lecturer
Department Biotechnology, Bioinformatics and Pharmaceutical Sciences
Institute/University Jaypee University of Information Technology
Address Waknaghat, P.O. Dumehar Bani, Kandghat, District
Solan- (H.P.) INDIA PIN: 173215
Telephone 01792-239387
Fax: 01792-245362 E-mail: [email protected]
Number of Research projects being handled at present: One
15b. Name Ms. Silpi Chanda
Date of Birth 13/03/1979
Designation Assoc. Lecturer
Department Biotechnology, Bioinformatics and Pharmaceutical Sciences
Institute/University Jaypee University of Information Technology
Address Waknaghat, P.O. Dumehar Bani, Kandghat, District
Solan- (H.P.) INDIA PIN: 173215
Telephone 01792-239353
Fax: 01792-245362 E-mail: [email protected]
Number of Research projects being handled at present: None
5
PART III: TECHNICAL DETAILS OF PROJECT
16. Introduction
16.1 Origin of the proposal
―Let your food be your medicine‖ exclaimed Hippocrates. Herbs, spices and other nutritional
substances are the oldest form of medicine known to man. The relationships between the human
being and plants are very close throughout the development of human health care system. A
large number of plants used in the traditional practice have now become a part of the modern
health care system and have been widely explored as supplements, and/or as alternatives to
conventional medicine.2 However, foods being exceedingly complex packages of chemicals and
compounds, do not deliver a single biological effect, as do pharmaceutical drugs designed to
accomplish a specific purpose. Ethno-botanical studies in India and abroad have revealed that
there is large scope for the development of new drugs from plants especially those used by
tribals are yet unexplored. So evaluation of ethno-botanical plants, preparation and
standardization of the extract or isolation of new chemical substances from tribal plants could be
exploited to identify and develop drug like molecules, which will not only be cost effective but
comparatively safer than the modern medicines.
In view of the importance of ethno-medicinal plants, an extensive field survey was done among
the tribal family residing in and around Agartala to identify valuable plants which have common
use among the various tribal communities for the treatment of gastrointestinal ulcer. The survey
indicated that out of nineteen tribal communities, eleven were using Paederia foetida for gastro
intestinal diseases — which seems to be peptic ulcer by characteristics described by tribal
communities. Paederia foetida is one of the tribal plants used as edible as well as medicine for
gastric related problems in North–East region of India and other parts of Asia. A literature
review showed that this herb has also been used in gastritis in various parts of world.3 The plant
has been described in Ayurvedic Pharmacopoeia of India4 and in Wealth of India
5.
Paederia foetida is one of the ingredients of different Ayurvedic formulations viz.
Dasamularista, Mahanarayana oil, Sudard (used as analgesic and anti-inflammatory), Prasarini
Taila (used gout), Kubja Prasarini Taila etc.
The present study is proposed for bioguided fractionation to identify and isolate the marker
compound(s) and to formulate a herbal preparation after doing chemical modifications with the
aim to increase its activity against PUD.
16.2 Rationale of the study supported by cited literature
Gastrointestinal (GI) disorders are set to affect over 250 million people in the seven largest
pharma markets, by 2012.6 Among all GIT disorders, peptic ulcer is one of the most crucial
issue in intensive care units where critically ill patients have many known risk factors. At
present, the pharmaceutical prescription market to treat GI disorders is valued at just over $20
billion, reflecting that it is one of the largest and most important therapeutic areas. World wide
India has 5th
rank in peptic ulcer disease (PUD) caused deaths (death rate 12.37/Lakh
population) and in India it is the 18th
most common cause of death (1.20%).7 Though peptic
ulcer of stomach and duodenum was known in 1700s and there is revolution of understanding
and management of PUD after the discovery of H. pylori. PUD represents a world wide health
6
problem because of its high mortality and morbidity. The Mortality (min 4 & max 30 %) and
Morbidity (min 25 & max 89%) varies as it‘s a multifactorial disease. 8 5 - 15% of adult
population of world is suffering with PUD.9 Based on type of mechanism of action, a number of
treatments are available for peptic ulcer — eg. Use of Antacids, H2 blockers, Proton pump
inhibitors, antibiotic, and combination therapy (Figure 1).10
ProglumideACh
PGE2
HistamineGastrin
Adenyl
cyclase
_+
ATP cAMP
Protein Kinase(Activated)
Ca++
+
Ca++
Proton pump
KK+ H+
Gastric acid
Parietal cell
AntacidOmeprazole
Ranitidine
H2M3
Misoprostol
__
+
PGE receptor
+
+
+
+
Gastrin
receptor
__ Lumen of stomach
+
Figure 1 Different mechanism of action for treatment of PUD
But each category is having unavoidable limitations for example long term use of H2 blockers
cause hip fracture.11
High doses or long-term use of Proton pump inhibitors (PPIs) carry a
possible increased risk of bone fractures.12
Although PPIs are well-tolerated, there have been
reports and recent cases implicating acute interstitial nephritis (AIN) and progression to acute
renal failure (ARF).13
The other side effects of PPIs are osteoporosis, hepatitis, visual
disturbance14
. FDA approved double, triple & quadruple therapy (Table 1) also causes
treatment failure and the main reason is patient noncompliance due to concomitant use of
medicine.
Patients have to follow the combination therapy, as each category of medicine is having
different mechanism of action. Hence a single drug treatment fails to meet the need. For the
cheaper option if any category is removed, it leads to reduction in efficacy.
In this aspect, herbal formulation may be a better option as it might act through multiple
mechanisms of action. Herbal medicines have emerged as a unique approach for meeting the
need for safe, effective and relatively inexpensive new remedies.
7
Table 1: FDA approved double, triple & quadruple therapy
Category Times to take Duration (days) Total no. of tablet
Proton pump inhibitor + 2
14 196 Bismuth subsalicylate 525mg + 4
Tetracycline 500mg+ 4
Metronidazole 500mg 3-4
Proton pump inhibitor + 2
10-14 60-84 Clarithromycin 500mg + 2
Amoxicillin 1gm 2
Bismuth subsalicylate 525mg + 4 14 168
Tetracycline 500mg + 4
Metronidazole 500mg 3-4 Cheap option but efficacy reduced without
Proton pump inhibitor
Ranitidine bismuth citrate 400mg 2 7 42
Clarithromycin 500mg + 2 Cheap option but efficacy reduced without
Proton pump inhibitor Metronidazole 500mg 2
Hence an effective anti-ulcer herbal formulation—acting by multiple mechanisms of action
is required to heal the peptic ulcer as well as to effectively prevent their recurrence.
Concurrent use of NSAIDs especially in case of arthritic patients is one of the most common
aggressive factors. Therefore, we could develop a remedy which will not only target the ulcer
patients but also arthritic patients who has to take NSAIDs in their daily medication and always
increasing the risk of ulcer formation or the chances of recurrence. Therefore, we anticipate that
the standardization of Paederia foetida extract and its chemical modification to increase its
efficacy/potency, will impart a novel extract, which would be formulated.
16.3 Hypothesis
Ethno-medicinal plant Paederia foetida has common use among the various tribal communities
for the treatment of gastrointestinal problems in North–East region of India and other parts of
Asia. There are great chances to identify various plant products or extracts which might have
activity against peptic ulcer. While pure products have their own benefits, plant extracts have
synergistic effects of various molecules present in the extract. Our aim is to enrich them by bio-
guided fractionation method. Chemically engineered extracts of these active extracts will give us
access to various semi synthetic compounds and we can compare their synergistic effects with
those of natural extracts. It is quite possible that those molecules which were not stable in
natural extract could be available in chemically engineered extracts. The combined approach and
stepwise pharmacological study will give knowledge about potency of the chemically
engineered extracts as compared to the mother extract. This study will provide extracts which
could have activity against peptic ulcer.
16.4 Key questions:
1. How could we exploit the traditionally used Indian medicinal herbs to develop drug like
molecules / extracts?
8
2. Would creation of natural product like libraries from plant extract enhance the efficacy
of mother extract?
16.5 Current status of research and development in the subject
International status and National status
Peptic ulcer is a common disorder of gastrointestinal system and is well described in Ayurveda.
A variety of plant and their products have been reported to possess antiulcer activity 15
including
Ficus arnottiana (Moraceae), Glycyrrhiza glabra (Ligominosae), Asparagus racemosus
(Asparagaceae), Nerium indicum (Apocynaceae), Cassia nigrans (Mimosoideae), Swertia
chirata (Gentianaceae), Alstonia Scholaris (Apocynaceae), Azadirachta indica (Meliaceae) etc.
Plant contains several active principles which are responsible for antiulcer activity viz.
flavonoids, terpenoids, alkaloids, tannins. 16,17
Paederia foetida has diverse biological activity
viz. anti-diarrhoel,18
hepatoprotective,19
anti-arthritic,20
anti-tussive,21
anti-inflammatory,22
antioxidant,23
analgesic,24
anti cancer,25
etc. in different pre clinical studies due to the presence
of different secondary metabolites. Traditional uses of P. foetida are tabulated in Table 2.
Table 2 : Traditional uses of P. foetida
A number of phytoconstituents of P. foetida are reported in literature — Iridoid glycoside,
alkaloids, Fatty acids,27
Embelin & Friedelano,28
hentriacontane, hentriacontanol, ceryl
alcohol, sitosterol, stigmasterol, campesterol, ursolic acid and epifriedelinol29
.
16.6 The relevance and expected outcome of the proposed study
This study will explore the preparation and standardization technique, estimation of phyto-
Plant part
used
Location
(State/Country) Traditional uses
Leaf India Dyspepsia, flatulence, gastritis and enteritis, intestinal catarrh,
astringent, diarrhoea, stomach ache, abdominal distension and urinary
retention, relieve urinary calculi and dysuria,26a
flatulence and
rheumatism.
Assam, Allergy26d
, in gastralgia, post natal pain and bleeding26e
diarrhoea and
dysentery,26f-I
as vegetables26f
abdominal pain26j
Tripura As vegetable, diuretic, in diarrhoea, infection26k, l
Andhra Pradesh As vegetable26m
Arunachal
Pradesh,
Urinary disorder, kidney stone and digestive problem26n
also with rice as
vegetables in indigestion,26o
in gastric trouble, to clean stomach and
against stomach swelling and diarrhoea,26p
gastritis and loose motion26q
Sikkim and
Darjeeling
Anti diabetic26r
Meghalaya As anti dote for snake bite26s
China In indigestion, carminative, as antidote for insect bites 26a
Philippine Rheumatism, fever, allergy 26a
Malaysia
Indonesia
Swellings and as a poultice to treat nose ulcer, applied to abdomen in
cases of retention of urine; as diuretic and to dissolve vesicle calculi. 26b
Bangladesh Diarrhoea, to relieve distention and flatulence26c
Root India Emollient and carminative, treatment of colic, spasms, rheumatism,
emetic, gout26a
, piles, spleen ailment,26c
Asthma, seminal weakness26c
Bark Philippine Emetic26a
Fruit Philippine Toothache26a
9
constituents as markers, molecular characterization of the plant metabolites to provide
standardized extract of Paederia foetida rich in bio active principles. The goal of this study is to
provide bioactive extracts (chemically engineered or natural fractions) and a herbal formulation
containing most active fraction. Exploration of chemically engineered extracts would be a useful
tool for chemical library of natural products as area which would strengthen the record of Indian
medicinal plants.
16.7 Preliminary work done so far
I. An extensive field survey among the tribal communities residing in and near Agartala,
Tripura was done. A list of plants used by tribal communities was prepared and
commonly used plant by all communities was chosen (Paederia foetida) for current
studies.
II. Raw material was collected from the tribal area of Agartala and authenticated from
NISCAIR, New Delhi. (authentication Ref No. NISCAIR/RHMD/Consult/2010-
11/1442/40).
Figure 2 Antiulcer effect P. foetids
III. The leaves of Paederia foetida were dried at room temperature and extracted with
methanol using soxhlet apparatus (Yield of extraction was 36.21% w/w).
IV. Toxicological studies were done and dose tolerable found to be upto 2000 mg /kg body
weight. Biological activity for PUD was evaluated by three different models viz.
indomethacin-pylorus ligation induced ulcer, alcohol induced gastric ulcer and wate
immersion stress induced ulcer (WISIU) Ulcer protection represented graphically
(Figure. 2) for the dose of 100 and 200mg/kg body weight for each model respectively.
72.98
59.4562.5
78.5872.97
67
82.89 81.08
70
Indomethacin -pylorus ligation model
Alcohol induced gastric ulcer model
WISIU model
Anti Ulcer Effect of P. foetida
100 mg Extract 200 mg Extract Standard Drug
Figures represent %ase of ulcer protection
10
17. Specific Objectives:
Standardization of P. foetida extracts.
Bioassay guided fractionation leading to the identification and isolation of marker(s)
components
Chemical modification of most bioactive fractionate followed by its evaluation for
antiulcer activity
Comparison of activities of fractionates and their chemically engineered extracts
To develop a suitable herbal formulation from modified P. foetida extract for peptic
ulcer disease (PUD).
18. Work Plan:
Field Survey and collection of Plant Material: Field Survey has already been done. Adequate
amount of plant material was collected for initial work.
In-vitro method
Determination of Anti-Helicobacter pylori activities
1. Preparation of media: 24 g of Coloumbia agar was dissolved in 1.0 litre of re-distilled water
and autoclaved. To 950ml of this agar 50ml of sheep blood was mixed at 450C in addition, 28g
of Brain Heart Infusion broth was dissolved in 925 ml of re-distilled water and autoclaved. Then
75ml of heat-inactivated foetal calf serum was mixed to this broth at about 450C.
2. Organism and its growth: A Helicobacter pylori bacterial strain was cultured under micro-
aerobic conditions of 5% O2, 15% CO2 & 80% N2 at 370C on Columbia agar supplemented by
5% sheep blood.
3. Preparation of solutions :Sample solution (100mg & 200mg) were taken in 5ml of sterile N,
N-dimethyl formamide (DMF). Standard solution was prepared by dissolving 500 mg of
amoxicillin and Clarithromycin in 5ml of sterile DMF.
4. Procedure of anti-microbial testing methods
Turbidity method: Test sample, standard Sample & sterile DMF were added to 5ml of Brain
Heart Infusion broth supplemented by 7.5% heat activated calf serum separately. The tubes were
inoculated with H. Pylori strain (approximately 1.5X105 CFU/ml) and incubated under micro-
aerobic conditions (of 5% O2, 15% CO2 & 80% N2) at 370C for 72 hours. The turbidity of Brain
Heart Infusion broth under trials was read at 600 nm against the blank.
Inhibitory zone method : 50µl of Test sample, standard Sample & sterile DMF were added in the
holes on Colombia agar with 5% sheep blood plates separately. The plates were then inoculated
with the H. Pylori strains and incubated at 370C for 72 hours under micro –aerophilic conditions.
The plates were checked for the inhibitory zones around the wells in the agar media and
diameters of the zones of inhibition were measured. The results showed by the sample compared
with standard.
11
In-vivo method
Model 1 : Indomethacin-pylorus ligation-induced ulcer30
Rats/mice of either sex divided into five groups (n=5) will be taken. All the groups (except
group 1) will receive indomethacin (25mg/kg s.c.) once daily for three days. Group 1 will be
treated with vehicle (1ml distilled water/kg p.o.). Group 2 will be treated with indomethacin
(25mg/kg s.c.). Sample extract will be administered at standardized doses (obtained from dose
response studies) to group 3 & 4 respectively. Ranitidine (50 mg/kg p.o.) will be administered to
group 5. Methanolic extract or ranitidine will be administered to the respective groups 30 min
before each indomethacin treatment.
Surgical procedure30,31
On the fourth day after the treatment, surgical procedure will be performed. The rats/mice will
be fasted 24 hours before the starting of surgical procedure and provided free access to water
during this period. Each rat will be anaesthetized with Ketamine (45 mg/kg i.p.) and xylazine (5
mg/kg i.p.) and the abdomen will be exposed through a midline incision. The pylorus will be
located and ligated tightly with silk suture and stitched. Four hours after pylorus-ligation, the
animals will be sacrificed by cervical dislocation.
Determination of gastric volumes, pH and acid output30,32
The gastric contents from sacrificed rats/mice will be collected after 4 hours of pylorus ligation.
The gastric content will be centrifuged at 4000 rpm for 10 minutes. Volume, pH and acidity of
the supernatant of gastric contents will be measured precisely. The acid outputs will be
calculated by following equation:
Model 2 : Alcohol induced gastric ulcer33
The animals will be divided into five groups, each consisting of five rats/mice. In this case ulcer
will induce by administering 70% alcohol (10 ml/kg p.o.). All animals will be fasted for 36
hours before administration of alcohol. Group 1 will receive 1 ml distilled water/kg p.o. Group 2
will receive 70% alcohol (10 ml/kg, p.o. ) to induce gastric ulcer. Group 3 & 4 will receive
sample extract. Sucralfate will be administered to fifth group as reference standard drug at the
dose of 100 mg/kg, p.o. They will be kept in specially constructed cages to prevent coprophagia
during and after the experiment. The animals will be sacrificed by cervical dislocation and ulcer
score will be recorded.
Model 3 : Water immersion stress induced ulcer (WISIU) 34
Group 1 will receive 1 ml distilled water/kg p.o. Group 2 and 3 will receive sample extract at the
standardized doses (obtained from dose response studies). Group 4 will receive Lansoprazole (8
mg/kg). After treatment animals will be allowed to swim in a glass cylinder having ice cold
Acid out put (µEq/hr) = Acidity (mEq/L) X Vol. of gastric juice (mL/4hr)
12
water (4oC).
35 Animals will be sacrificed by cervical dislocation and gastric lesion in the
glandular region will be located in the gastric mucosa as elongated black red lines parallel to the
long axis of stomachs. The length (mm) of each lesion will be measured and lesion index will
calculated.
Plant Extract and Bio-guided Fractionation:
For preliminary studies, plant extract has been prepared using standard procedures.36
We would
check activity of crude extract using three pharmacological models to identify the best model for
study. The plant extracts will be then subjected to bioactivity guided fractionation to identify
active extract fractions. This suitable model will be used for screening of fractionates. We would
carryout chemical modification of active fractions and would test if they have better activity as
compared to mother fraction.
Preparation of chemically engineered extracts
Our approach to generate modified extract is based upon concept of chemically engineered
extracts (CEEs) preparation.1 Diversification of the components of natural extracts through
various functional group transformations could generate unique extracts. The reactions would be
selected on the basis of standard functional group tests.37
(Figure 3)
Following are the selected classes of reactions, which we will use once extracts are prepared and
fractionated.
Imine Formation Hydrazone Formation
Oxime Formation Disulfide Exchange
Sulphonylation Esterification & Hydrolysis
Oxidation-Reduction Reactions Bromination
Figure 3 Chemically Engineered Extracts
Formulation: The most active fractions will be combined and formulated. The dried extract will
be suspended in 0.3% carboxy methylcellulose solution.
13
18.1 Work Plan: Work plan is sketched in following scheme -1.
Scheme-1 Work Plan
Year 1: Plant Extract Preparation, Fractionation, Pharmacological Study
During first year of investigation, we will focus our studies on identification of antiulcer activity
in extract fractionation, their modification and method development of preparation of chemically
modified extracts. .
Year 2: Identification, Chemical Modification (Chemically Engineered Extract),
Pharmacological Study
Selection of plant and plant material
(leaf & stem) based on survey
100% pet
ether extract
100%
dichloromethane
extract
100% methanolic
extract
100% aqueous
extract
Bio guided fractionation (at least one in-vitro and two in-vivo method)
Identification and isolation of marker(s)
Chemical modification of most active fraction
Standardization of extract
Evaluation of activity and comparison with mother
extract/fractions
Formulation of suitable herbal preparation
14
During second year, we plan to execute our methods developed during Year I and prepare
chemically engineered extracts and their pharmacological activity.
Year 3: Pharmacological Studies and herbal formulation, Comparisons of activities,
Compilation of results and Final Report
This year we will focus our efforts in comparative studies, compilation of results and work will
be published in research journals.
19. Timelines:
Period of study Achievable targets
6 Months Procurement of Instruments, Chemicals, appointment of SRF
Preparation of different Extracts,
12 Months Phytochemical & chromatographic (TLC / HPTLC / HPLC) profiling,
pharmacological study bioassay guided fractionation at least one in-
vitro and two in-vivo model.
18 Months Identification of Most Active Fraction , Pharmacological Studies
identification and isolation of marker(s)
24 Months Preparation of Chemically Engineered Extract
30 Months Pharmacological Studies of chemically engineered extracts, at least one
in-vitro and two in-vivo model. Comparisons of activities
36 Months Formulation of suitable herbal preparation
Compilation of results and Final Report
20. Name and address of 5 experts in the field
Sr.No. Name Designation Address
1. Prof. Rajesh
Kumar Goel
Associate
Professor &
Head
Department of Pharmaceutical Sciences & Drug
Research, Punjabi University, Patiala,Punjab.
Pin -147002
2. Dr. Mohd. Ali Professor Department of Pharmacognosy and
Phytochemistry, Faculty of Pharmacy, Jamia
Hamdard, New Delhi 110062,
3. Dr. Biplab De Asst. Professor Department of Pharmaceutical chemistry, Regional
Institute of Pharmaceutical Science and
Technology, Central University Tripura 799006
4. Prof. S. M.
Sondhi
Professor Department of Chemistry, Indian Institute of
Technology Roorkee - 247667
5. Prof. Anil
Kumar
Associate
Professor
University Institute of Pharmaceutical Sciences
Punjab University Chandigarh
References:
15
1 a) Ramallo, A. I.; Salazar, M. O.; Mendez, L.; Furlan; R. L. E. Chemically Engineered Extracts: Source of
Bioactive Compounds Acc. Chem. Res. 2011, 44, 241– 250 b) López S.NRamallo I.ASierra M.GZacchino S.AFurlan R.L. Chemically engineered extracts as an alternative source of bioactive natural product-like compounds Proc Natl Acad Sci 2007; 104; 441-444.
2 Fabricant DS, Farnsworth NR, The Value of plants used in traditional medicine for drug discovery. Environmental Health Perspects 2001, 109 (Suppl 1), 69–75.
3 Kar A, Borthakur SK Wild vegetables of Karbi-Anglong district Assam Nat. Prod. Radiance 2008, 7, 448-460. 4 Ayurvedic Pharmacopoeia of India, part I Vol II, Govt. of India, Ministry of Health and Family Welfare Dept of
Ayush, Delhi,2009 p-145-148 5 Wealth of India. Raw Material Vol Vii 2001, National Institute of Science Communication, CSIR, New Delhi
p210-211 6 http://www.leaddiscovery.co.uk/reports/459/Gastrointestinal_Disorders_Market_Intelligence_to_2012/
Last accessed on September 20, 2011. 7 http://www.worldlifeexpectancy.com/country-health-profile/india (Last visited on September 15, 2011) 8 Kocer B; Surmeli B; Solak C; Unal B; Bozkurt B; Yildirim O; Dolapci M; Cengiz O Factors Affecting Mortality
and Morbidity in Patients With Peptic Ulcer Perforation J Gastroenterol Hepatol. 2007;22, 565-570 9 Sharma SK, Maharjan DK, Thapa PB Hospital based analytic study of peptic ulcer disease in patients with
dyspeptic symptoms Kathmandu University Medical Journal 2009, 7, 135-138 10 Rang & Dale's Pharmacology HPD Rang, MM Ritter, JM Flower… - 2007 - Elsevier, Philadelphia 11 Yang YX, Lewis JD, Epstein S, Metz DC Long-term Proton Pump Inhibitor Therapy and Risk of Hip Fracture
JAMA. 2006, 296, 2947-2953. 12 Http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/
ucm213206. htm (Last Accessed on 20 Sept 2011) 13 Geevasinga N, Coleman PL, Webster AC, Roger SD Proton Pump Inhibitors and Acute Interstitial Nephritis
Clinical Gastroenterology and Hepatology. 2006;4:597–604 14 Viana de Miguel C, Alvarez GM, Sánchez SA, Carvajal G-PA. Lansoprazole-induced hepatitis Med Clin (Barc).
1997, 108, 599 15 a) Gadekar, R.; Singour, PK.; Chaurasiya, PK.; Pawar, RS.; Patil, UK. A potential of some medicinal plants as an
antiulcer agents pharmacog rev 2010,4,136-146 b) Sen, S.; Chakraborty, R.; De, D.; Mazumder, J. plants and phytochemical for peptic ulcer: An overview Pharmacog. rev 2009, 3, 270-279 c) Gulcin, I, Kufrevioglu, O. I.; Oktay, M.; Buyukokuroglu, M. E. Antioxidant, antimicrobial, antiulcer and analgesic activities of nettle ( Urtica dioica L.) Journal of Ethnopharmacology 2004, 90, 205-215 d) Malairajan, P.; Gopalakrishnan, G.; Narasimhan, G.; Veni, KJ. K.; Kavimani, S. Anti-ulcer anctivity of crude alcoholic extract of Toona ciliata Roemer (heart wood) Journal of Ethnopharmcology 2007, 110, 348-351..
16 Mota, KSL; Dias, GEN; Pinto, MEF; Luiz-Ferreira, A.; Souza-Brito, ARM; Hiruma-Lima, CA.; Barbosa-Filho, JM; Batista L. M. Flavonoids with Gastroprotective Activity Molecules 2009, 14, 979-1012
17 Falcão H S.; Leite JA.; Barbosa-Filho JM.; Athayde-Filho PF; Chaves, M. C. O.; Moura, M. D.; Ferreira, A. L.; Almeida, A. B. A.; Souza-Brito, A. R. M.; Diniz, M. F. F. M.; Batista, L. M. Gastric and Duodenal Antiulcer Activity of Alkaloids: A Review Molecules 2008, 13, 3198-3223
18 Afroz S, Alamgir M, Khan MT, et al. Antidiarrhoeal activity of the ethanol extract of Paederia foetida Linn. (Rubiaceae), J Ethnopharmacol, 2006, 105, 125-130.
19 De S, Ravishankar B, Bhavsar GC, Evaluation of paederia foetida for Hepatoprotective and Anti-inflammatory Activities, Indian J Nat. Prod, 1993, 9, 7-10.
20 Chaturvedi GN, Singh RH, Experimental studies on the antiarthritic effect of certain indigenous durgs, Indian journal of medical research, 1965, 53, 71-80.
21 Nosalova G, Mokry J, Ather A, Khan MTH. Antitussive Activity of the Ethanolic Extract of Paederia foetida (Rubiaceae family) in Non-Anaesthetized Cats, Acta Vet. Brno, 2007, 76, 27-33.
22 De S, Ravishankar B, Bhavsar GC, Investigation of the anti-inflammatory effects of Paederia foetida, J of Ethnopharmacology, 1994, 43, 31-38.
23 Kumar V, Gogoi1 BJ, Meghvansi MK, et al. Determining the antioxidant activity of certain medicinal plants of sonitpur, (Assam), India using DPPH assay, Journal of Phytology, 2009, 1, 49–56.
24 Md Hossain M, Mohammad SA, Saha A, Md. Alimuzzaman, Antinociceptive activity of whole plant extracts of Paederia foetida, J Pharm Sci, 2006, 5, 67-69.
25 Costa-Lotufo LV, Khan MTH, Arjumand Ather, Studies of the anticancer potential of plants used in Bangladeshi folk medicine, Journal of Ethnopharmacology 2005, 99, 21–30.
16
26 a) Compendium of Medicinal Plants Used in Malaysia, 2002 Herbal Medicine Research Centre, Institute for
Medical Research, Kuala Lumpur, 2002,191-192. b) The Wealth of India, Raw material Vol VII. National Institute of Science Communication, CSIR, New Delhi, 2001, 210-211. c) http://www.stuartxchange.org/Kant d) Kalita D, Deb B, Folk medicines for some diseases prevalent in Lakhimpur district of Brahmaputra valley, Assam, Nat Prod Radiance, 5(4), 2006, 319-322. e) Purkayastha J, Nath SC, Biological activities of Ethnomedicinal claims of some plant species of Assam, Indian Journal of Traditional Knowledge, 2006, 5, 229-236. f) Barua U, Hore DK, Sarma R, Wild edible plants of Majuli island and Darraug districts of Assam, Indian Journal of Traditional Knowledge, 2007, 6, 191-194. g) Borah PK Gogoi P, Phukan AC, J Mahanta, Traditional medicine in the treatment of gastrointestinal diseases in upper Assam, Indian Journal of Traditional Knowledge, 2006, 5, 510-512. h) Basumatary SK, Ahmed M, Deka SP, Some medicinal plant leaves used by Boro (Tribal ) people of Goalpara district, Assam, Nat prod radiance, 2004, 3, 88-90. i) Kar A, Borthakur, Medicinal plants used against dysentery, diarrhea and cholera by the tribes of erstwhile Kameng district of Arunachal Pradesh, Nat prod radiance, 2008, 7, 176-181. j) Kalita D, Phukan B, Some Ethnomedicine used by the tai Ahom of Dibrugarh district, Assam India, Indian Journal of Natural Prod and Resources, 2010, 1, 507-511. k) Paushali Das, Wild tribal plants of Tripura tribes, 1
st ed, Tripura Tribal
Cultural Research Institute & Museum, Govt of Tripura, 1997,57-58. l) Chanda S, De B, Tiwari RK. Traditional and ethnobotanical investigation of some edible plants among th etribs of Tripura, India. In: Choudhury MD, Sharma GD, Choudhury S, Talukdar AD, Status and conservation of bio-diversity in North East India, 1
st ed.
Delhi Swastik publications, New Delhi, 2011, 118-124. m) Reddy KN, Pattanaik C, CS Reddy, Raju VS, Traditional knowledge on wild food plants in Andhra Pradesh, Indian Journal of Traditional Knowledge, 2007, 6, 223-229. n) Sarmah TR, Adhikari D, Majumdar M, Arunachalan A. Raditional medicobotany of chakma community residing in the Northwestern periphery of Namdapha National park in Arunachal Pradesh, Indian Journal of Traditional Knowledge, 2008, 7, 587-593. o) Kagyung R, Gajurel PR, Rethy P, Singh B, Ethnomedicinal plants used for gastrointestinal disease by Adi tribes of Dehang-Debang Biosphere Reserve in Arunachal Pradesh, Indian Journal of Traditional Knowledge, 2010, 9, 496-501. p) Srivastava RC, Singh RK, Apatani community, Mukherjee TK, Indigenous biodiversity of Apatani plateau: Learning on biocultural knowledge of Apatani tribe of Arunachal Pradesh for sustainable live hoods. Indian Journal of Traditional Knowledge, 2010, 9, 432-442. q) Sumpam Tangjang, Nima D Namsa, Chocha Aran, Anggu Litin, An ethnobotanical survey of medicinal plants in the Eastern Himalayas zone of Arunachal pradesh, India. J Ethnopharmacology, 2011, 134, 18-25. r) Chhetri DR, Parajuli P, Subba GC, Antidiabetic plants used by Sikkim and Darjeeling Himalayan tribes, India, Journal of Ethnopharmacology, 2005, 99, 199–202. s) Hynniewta SR, Kumar Y, Herbal remedies among the Khasi traditional healers and village folks in Meghalaya, Indian journal of traditional knowledge, 2008, 7, 581-586.
27 Shukla YN, Lloyd HA, Morton JF, Kapadia GJ. Iridoid glycosides and other constituents of Paederia foetida. Phytochem 1976; 15, 1989-1990.
28 Laurence L. Goodman and Gilman's The Pharmacological basis of Therapeutics. 9th Edition. UAS: Mc Graw-Hill companies Inc.; 1998
29 Ahmad MU, Islam MR, Huo E, Khan MW, Gupta S. Chemical constituents from Paederia foetida leaves. J Bangladesh Acad Sci 1991; 15, 19-22.
30 Yoshikawa, TNaito, YNakamura, SKaneko, T1993. Effect of Rabamipide on lipid peroxidation and gastric mucosal injury induced by indomethacin. Arzneim-Forsch/Drug Res. 43, 1327-1330.
31 Goel, R.KChakrabarti, ASanyal, A.K1985.The effect of biological variables on the anti ulcerogenic effect of vegetable plantain banana. Planta Medica 2, 85-8.
32 Kikuko AK, Shinichi Y, Hiroshi and O Susumu 1996. Effects of the nova histamine H2 receptor antagonist (±)-(E)-1-[2-hydrpxy-2-(4-hydroxyphenyl)ethyl]-3-[2-[[[5-(methyl amino) methyl-2-furyl] methyl]thio] ethyl]-2-(methylsulfonyl) guanidine on gastric secretion and gastroduodenal ulcers in rats. Arzneim-Forsch/Drug Res; 46:117-85.
33 Aguna, C.NUkwe, C.,1997. Gastrointestinal activities of Sterculia tragacantha leaf extract. Fitoterapia 68, 127-131.
34 Tanaka, TMorioka, YGebert, U.,1993. Effect of novel xanthene derivative on experimental ulcer in rats. Arzneim-Forsch/Drug Res. 43, 558-562.
35 Bhattacharya, S.KBhattacharya, D1982. Effect of restraint stress on rat brain serotonin. Journal of Bioscience 4, 267-274.
36 Houghton, P.JRaman, A1998. Laboratory handbook for the fractionation of natural extracts. Chapman and Hall, London.
37 Furniss, B.S. 1989. Vogel's Textbook of Practical Organic Chemistry, 5th
edn, Pearson Education India, New Delhi
17
PART IV: BUDGET PARTICULARS
Budget (In Rupees)
A. Non-Recurring (e.g. equipments, accessories, etc.):
S. No. Item Year 1
(in lakhs
Year 2
(in lakhs
Year 3
(in lakhs
Total (in
lakhs
1 FT IR SYSTEM 15 0 0 15.0
Sub-Total (A) 15 Lac
B. Recurring
B.1 Manpower
S.No. PositionNo. Consolidated
Emolument
Year 1
(in
lakhs)
Year 2
(in
lakhs)
Year 3
(in
lakhs)
Total
(in lakhs)
1. SRF - one Rs. 18,000 +
HRA 2.376 2.376 2.376 7.128
Sub-Total (B.1) = 7.128
B.2 Consumables
S. No. Item Year 1 Year 2 Year 3 Total (in
lakhs)
1.
Consumables for isolation,
purification and chemical
modification – various adsorbants,
solvents, HPLC Grade solvents,
Reagents and chemicals for
derivatization, modification of
extracts. Various metal Catalysts.
Other everyday use chemicals and
reagents for running Columns, TLC
and Reactions isolation and
purification reagents, glassware,
plasticware, UV-Cabinet etc.
3.0 3.0 2.0 8.0
2. Animal Studies 1.5 1.5 1 3.5
3.
NMR , IR and HPLC, LC-MS
analysis (approx @2000/- Per
sample) approx 100 samples for 3
years
2.0 2.0 2.0 6
Sub-Total (B.2) = Rs. 17.5 lakhs
18
Other items Consolidated Emolument Year 1 Year 2 Year 3 Total (in
lakhs)
B.3
Travel
Travel (Only inland travel) 0.5 0.5 0.5 1.5
B.4
Contingency
Other costs/Contingency
costs
2.0 2.0 2.0 6.0
B.5 Overhead
(If applicable)
Overhead As applicable
Sub-total of B (B.1+B.2+B.3+B.4): 7.128 + 17.5 + 1.5 +6.0= 32.128 lakhs
Grand Total (A + B): = 47.128 lakhs + Overheads As applicable
Part V: EXISTING FACILITIES
Resources and additional information
1. Laboratory: Chemistry Labs, Biochemistry Labs, Molecular Biology Labs, Tissue Culture
Labs
a. Manpower: Sr. Lab Technician (2); Lab Technician (3), Clerk (1), Peon (2).
b. Other resources: Animal House, glass house.
c. Equipments:
S.
No.
Name of equipment/accessories Make Funding
agency
Year of
procuremen
t
2. UV-Visible Spectrophotometer Elico JUIT 2003
3. Thermal Cyclers Applied Biosystems JUIT 2003
4. Vertical Gel Electrophoresis
System
Bangalore Genei JUIT 2003
5. SubmarineDNA Electrophoresis Bangalore Genei JUIT 2003
6. Low Temp Freezer (-20ºC) Vestafrost JUIT 2003
7. Ice Flaking Machine Manitowoc JUIT 2003
8. Water Purification System Millipore JUIT 2003
9. Electronic Analytical Balance Citizen JUIT 2003
10. pH Meter Elico JUIT 2003
11. Laminar Air Flow S M International JUIT 2003
12. High Speed Centrifuge Beckman JUIT 2003
13. Table Top Shaker Kuhner JUIT 2003
14. B.O.D. Incubators Hicon JUIT 2003
15. UV Transilluminator Bangalore Genei JUIT 2003
16. Plant Tiisue Culture Chamber Saveer JUIT 2003
17. Magnetic Stirrers Remi JUIT 2003
18. Incubator Shaker Kuhner JUIT 2003
19. Autoclaves Hicon JUIT 2003
20. Digital Camera Olympus JUIT 2003
21. Incubator (water bath) GFL (German) JUIT 2003
22. Clinical Centrifuges Olympus JUIT 2003
19
23. Walk-in-cold room Blue-Star JUIT 2003
24. Spectronic 20D+ Thermospectronic JUIT 2003
25. Electronic digital analytical
balance
Analytica JUIT 2004
26. Gel Doc BioRad JUIT 2005
27. LP system BioRad JUIT 2005
28. Low Temp Freezer (-80oC) New Buns Wick JUIT 2006
29. Freeze Dryer New Buns Wick JUIT 2006
30. HPLC System Waters JUIT 2006
31. Gas Chromatography Agilent Tech. JUIT 2006
32. Gene Pulser Xcell Total System BioRad JUIT 2007
33. Sequi-Gen GT Sequencing Cell BioRad JUIT 2007
34. CHEF-DR III Variable Angle
System
BioRad JUIT 2007
35. DNA Fluorometer BioRad JUIT 2007
36. Sonicator BioRad JUIT 2007
37. Phase Contrast Microscope Nikon JUIT 2007
38. In situ Setrilizable Fermentor 10L New Burns Wick JUIT 2007
39. CO2 Incubator New Buns Wick JUIT 2007
40. Chef DRIII Chiller Bio Rad JUIT 15/1/2008
41. Laboratory Spray drier Labultima/Mumbai JUIT 17/7/2008
42. Plant growth chamber Vista Bio-Cell Pvt.
Ltd.
JUIT 2/8/2008
43. Ultra Low Temp. Freezer (-80o C) New Brunswick
Scientific
JUIT 31/8/2008
44. Gel Doc System Alpha Ino Tech JUIT 30/9/2008
45. Incubator with Shaker
(MICROPROCESSOR)
New Brunswick
Scientific
JUIT 30/9/2008
46. PCR Machine 2 Nos Applied Biosystems JUIT 10/3/2008
47. Autoclave Mod. MLS3781 Sanyo SCIMED Asia Pvt.
Ltd.
JUIT 7/10/2008
48. Autoclave Mod. MLS3781 Sanyo SCIMED Asia Pvt.
Ltd.
JUIT 7/10/2008
49. 2 D PAGE system Bio Rad JUIT 31/12/2008
50. Atomic Absorption
Spectrophotometer
Perkin Elmer JUIT Jan. 2009
51. Centrifuge Allegrax Beckman Coulter JUIT 26/9/2009
52. RT PCR Biorad JUIT 5/11/2010
53. Millipore water Purification
System
Millipore JUIT 9/12/2010
54. Deep Freezer -80 D Newbrunswick JUIT 3/1/2011
55. Prep HPLC Waters DBT Oct 2011
20
PART VI: DECLARATION/CERTIFICATION
It is certified that
a) the research work proposed in the scheme/project does not in any way duplicate the work
already done or being carried out elsewhere on the subject.
b) the same project has not been submitted to any other agency/agencies for financial support.
c) the emoluments for the manpower proposed are those admissible to persons of
corresponding status employed in the institute/university or as per the Ministry of Science
& Technology guidelines (Annexure-III).
d) necessary provision for the scheme/project will be made in the Institute/University/State
budget in anticipation of the sanction of the scheme/project.
e) if the project involves the utilisation of genetically engineered organism, it is agreed that
we will ensure that an application will be submitted through our Institutional Biosafety
Committee and we will declare that while conducting experiments, the Biosafety
Guidelines of the Department of Biotechnology would be followed in toto.
f) if the project involves field trials/experiments/exchange of specimens, etc. we will ensure
that ethical clearances would be taken from concerned ethical Committees/Competent
authorities and the same would be conveyed to the Department of Biotechnology before
implementing the project.
g) it is agreed that any research outcome or intellectual property right(s) on the invention(s)
arising out of the project shall be taken in accordance with the instructions issued with the
approval of the Ministry of Finance, Department of Expenditure, as contained in
Annexure-V.
h) we agree to accept the terms and conditions as enclosed in Annexure-IV. The same is
enclosed.
i) the institute/university agrees that the equipment, other basic facilities and such other
administrative facilities as per terms and conditions of the grant will be extended to
investigator(s) throughout the duration of the project.
j) the Institute assumes to undertake the financial and other management responsibilities of
the project.
Signature of Project Coordinator Signature of Executive Authority
of Institute/University with seal
Date : December 14, 2011 Date : December 14, 2011
Signature of Principal
Investigator
Signature of Co-
Investigator
Signature of Co-
Investigator
Date Date Date
21
PART VII: PROFORMA FOR BIOGRAPHICAL SKETCH OF INVESTIGATORS
Provide the following information for the key personnel in the order listed on PART II.
Follow this format for each person. DO NOT EXCEED THREE PAGES
Name : Kuldeep Singh
Designation : Sr. Lecturer
Department/Institute/University : Department of Biotechnology , Bioinformatics &
Pharmaceutical Sciences, Jaypee University of
Information Technology
Date of Birth : 01 November 1978 Sex (M/F): M
Telephone: 01792-239391 FAX: 01792-245362
Education (Post-Graduation onwards & Professional Career)
S. No. Institution Place Degree Awarded Year Field of Study
I. IIT Roorkee M.Sc 2001 Chemical Sciences
II. IIT Bombay Ph.D 2007 Chemical Sciences
A. Position and Honors
Position and Employment (Starting with the most recent employment)
S. No. Institution /Place Position From
(Date)
To (date)
1. Jaypee University of
Information Technology
Waknaghat
Senior Lecturer July, 2010 Continuing
2. Jaypee Institute of Information
Technology Noida
Senior Lecturer November,
2009
June, 2010
3. Sai Adventium Pharma Ltd,
Pune
Research Scientist Feb 2009 Nov 2009
4. IIT Bombay Research Associate 01.11.2008 31.01.2009
5 University of Strasbourg ,
France
Postdoctoral
Scientist
01.11 2007 31.10.2008
6 IIT Bombay Research Associate 14.06.2007 25.10.2007
Honors/Awards
2007-2008 Postdoctoral Fellowship by University of Strasbourg, France
2003-2006 CSIR Senior Research Fellowship
22
2001-2003 CSIR Junior Research Fellowship
2001 Qualified Graduate Aptitude Test in Engineering (GATE)- Percentile 95.18
2000 Qualified Joint CSIR-UGC Test for J.R.F and Eligibility for Lectureship (NET)
1999-2001 Fee ship during M.Sc. awarded by I.I.T. Roorkee for position in Merit list.
1997 Selected for Award of ICAR National Talent Scholarship in Agricultural
Sciences.
Professional Experience and Training relevant to the Project
Applicant has training in organic chemistry. He will take care of chemistry part of the project.
B. Publications Research Papers: 05
I. Kotha, S., Bansal, D.; Singh, K; and Banerjee, S.; Synthesis of a new fluorescent
macrocyclic [alpha]-amino acid derivative via tandem cross-enyne/ring-closing
metathesis cascade catalyzed by ruthenium based catalysts, Journal of Organometallic
Chemistry, vol 696, pp. 1856-1860 , 2011.[ Indexed in SCOPUS, Impact factor: 2.205]
II. Kotha, S., Vittal, S., Singh, K., and Deodhar, K. D., ―Strategic utilization of catalytic
metathesis and photo-thermal metathesis in caged polycyclic frames", Tetrahedron
Letters, vol.51, pp. 2301-2304, 2010.[ Indexed in SCOPUS, Impact factor: 2.538]
III. Kotha, S., and Singh, K., ―Cross-enyne and ring-closing metathesis cascade: A building-
block approach suitable for diversity-oriented synthesis of densely functionalized
macroheterocycles with amino acid scaffolds", European Journal of Organic Chemistry,
pp. 5909-5916, 2007.[ Indexed in SCOPUS, Impact factor: 3.016]
IV. Kotha, S., and Singh, K., ―N-Alkylation of diethyl acetamidomalonate: Synthesis of
constrained amino acid derivatives by ring-closing metathesis reaction", Tetrahedron
Letters, vol.45, pp. 9607-9610, 2004.[ Indexed in SCOPUS, Impact factor: 2.538]
V. Thallapally, P. K., Jetti, R. K., Katz,A. K., Carrel,H. L., Singh, K., Lahiri, K., Kotha,
S.,Bose, R., and Desiraju, G., ―Polymorphism of 1, 3, 5-trinitrobenzene induced by
trisindane additive", Angewandte Chemie International Edition, vol.43, pp. 1149-1155,
2004.[ Indexed in SCOPUS, Impact factor: 12.73]
Place : JUIT WAKNAGHAT Signature of Investigator
Date : December 14, 2011
23
PART VII: PROFORMA FOR BIOGRAPHICAL SKETCH OF INVESTIGATORS
Provide the following information for the key personnel in the order listed on PART II.
Follow this format for each person. DO NOT EXCEED THREE PAGES
Name : Silpi Chanda
Designation : Assoc. Lecturer
Department/Institute/University: Department of Biotechnology, Bioinformatics &
Pharmaceutical Sciences, Jaypee University of Information Technology, Solan,Pin 173215
Date of Birth : 13/03/1979 Sex (M/F) F
Education (Post-Graduation onwards & Professional Career)
Sl No. Institution
Place
Degree
Awarded
Year Field of Study
1 Oxford College of Pharmacy, Bangalore M. Pharm 2007 Pharmacognosy
A. Position and Honors
Position and Employment (Starting with the most recent employment)
Sl No. Institution Place Position From To (date)
1 Jaypee University of Information
Technology, Wakhnaghat, HP
Assoc. Lecturer Jan 2011 Till date
2 Innovative College of Pharmacy,
Greater Noida, UP under Uttar
Pradesh Technical University.
Lecturer Nov 2009 Dec 2010
3 College of Pharmacy, IILM, Greater
Noida, UP under Uttar Pradesh
Technical University.
Lecturer Oct 2008 Nov2009
4 Nutan Education Trust B. Pharmacy
college, Godhra, Gujrat Technical
University
Lecturer Dec 2007 Oct 2008
5 Torrel Cosmetics –Sister concern of
Torrent pharmaceuticals, Ahmedabad,
Gujrat
F & D Executive Feb 2007 Dec 2007
24
Honors/Awards
Four (04) year state scholarship under the Govt. of Tripura through out the tenure of B.
Pharmacy
Professional Experience and Training relevant to the Project
1. The applicant has been engaged in R&D projects on isolation and characterization of
phytoconstituents from Medicinal and Aromatic plants in Natural Remedies Pvt. Ltd.
Bangalore.
2. The applicant has experienced on various aspects of Chromatographic technique including
TLC, HPTLC and HPLC and method validation technique.
3. Drug testing at Central Drug Laboratory (CDL), Govt of Tripura, India.
B. Publications (Numbers only)
Books : None Research Papers: 07 Communication 02
List of publications:
S. Chanda, Shalini Kushwaha and Raj kumar Tiwari. 2011. Garlic as food, spice and medicine :
A prespective. Journal of Pharmacy Research. 4(6): 1857-1860
S. Chanda, Manish Bagga and Raj kumar Tiwari. 2011. Microneedles in transdermal drug
delivery : An unique painless option. International Journal of Pharmacy 2(4):72-78
B De, A. Chakraborty, T Majumder, S. Chanda and B.B. Goswami. 2011. Evaluation of
Spermicidal and Antimicrobial Activities of methanolic extract of Leucas aspera and Structural
elucidation of separated active component. Asian Journal of Chemistry, 23(2) : 826-828.
B De, A. Chakraborty, T Majumder, S. Chanda and B.B. Goswami. 2011. Evaluation of
Spermicidal and anticoagulant activities of methanolic extract of Mimosa pudica and Structural
elucidation of separated active component. Asian Journal of Chemistry. 23(2): 832-834.
R. K. Tiwari, S. Chanda, M. Deepak, B. Murli and A. Agarwal. 2010. HPLC method validation
for simultaneous estimation of Madecassoside, Asiaticoside and Asiatic acid in Centella
asiatica. Journal of Chemical and Pharmaceutical Research. 2(3) : 223-229.
S. Chanda & Padmaa M Parakh. 2008. Crateava nurval-Buch-a review In Prarmacog. Rev.
2(3):18-21.
De, S. Raha, S. Chanda, B. Debbarma 2007. Antibacterial evaluation of the extracts of edible
parts of fewplants used by tribal people of Tripura India. In the Journal of Pure &Applied
Microbiology- An International Research Journal of Microbiology. 1:65-68
Place : JUIT WAKNAGHAT Signature of Investigator
Date : December 14, 2011
25
PART VII: PROFORMA FOR BIOGRAPHICAL SKETCH OF INVESTIGATORS
Provide the following information for the key personnel in the order listed on PART II.
Follow this format for each person. DO NOT EXCEED THREE PAGES
Name : M. Udayabanu
Designation : Lecturer
Department/Institute/University : Department of Biotechnology, Bioinformatics &
Pharmaceutical Sciences, Jaypee University of
Information Technology
Date of Birth : 01 Sep’1977 Sex (M/F) M
Education (Post-Graduation onwards & Professional Career)
Sl No. Institution
Place
Degree
Awarded
Year Field of Study
1. SGSITS, Indore M.Pharm 2002 Medicinal and
Pharmaceutical Chemistry
2. Dr.Ambedkar Center for
Biomedical Research,
Delhi University.
PhD. Thesis
Submitted
Biomedical Sciences
B. Position and Honors
Position and Employment (Starting with the most recent employment)
Sl No. Institution / Place Position From (Date) To (date)
1 Jaypee University of Information
technology, Waknaghat
Lecturer 1.7.2010 Till date
2 Jaypee Institute of Information
Technology, Noida Lecturer Nov 2009 June 2010
3 Dr.B.R.Ambedkar center for
Biomedical research, Delhi
University
Teaching
Assistant August 2005 June 2006
4 RKGIT, Ghaziabad Lecturer Oct 2004 June 2005
5 RMSITS, Madhya Pradesh Lecturer Feb 2002 Sep 2004
26
Honors/Awards
a. Recipient of Junior research Scholarship from AICTE
b. Recipient of Senior Research Fellowship from ICMR
c. Member of Academic council for Post Graduate in S.G.S.I.T.S., Indore, INDIA
d. Ranked # 12 in national level Graduate Aptitude Test in Engineering exam with
99.61 percentile conducted by Indian Institute of Technology in 2000
e. Ranked as #1 in educational achievement at undergraduate level
Professional Experience and Training relevant to the Project
Expertise in animal handling
Pharmacological screening of plant extract like Withania extract, Hypeicum extract,
Stringinging nettle extract
C. Publications (Total number of research articles published: 04)
List maximum of five recent publications relevant to the proposed area of work.
1. Udayabanu, M., Kumaran, D., Nair, R.U., Srinivas, P., Bhagat, N., Aneja, R., Katyal, A.
Nitric oxide associated with iNOS expression inhibits cetylcholinesterase activity and induces
memory impairment during acute hypobaric hypoxia‖ Brain Res, Vol. 1230, pp. 138-49, 2008.
2. Kumaran, D., Udayabanu, M., Kumar, M., Aneja, R., Katyal, A., ―Involvement of
angiotensin converting enzyme in cerebral hypoperfusion induced anterograde memory
impairment and cholinergic dysfunction in rats‖ Neuroscience, Vol.155, pp. 626-39, 2008.
3. Kumaran, D., Udayabanu, M., Nair, R.U., Aneja, R., Katyal, A., ―Benzamide protects
delayed neuronal death and behavioural impairment in a mouse model of global cerebral
ischemia‖ Behav Brain Res, Vol. 192, pp. 178-84, 2008.
4. Udayabanu, M., Kumaran, D., Katyal, A. Free chelatable zinc modulates the cholinergic
function during hypobaric hypoxia induced neuronal damage: An in-vivo study. Neuroscience.
(Accepted)
C. Research Support
Ongoing Research Projects
Sl No. Title of Project Funding Agency Amount Date of sanction and Duration
1 Formulation of an
antidepressant/stress
reliever drug based on
St John‘s Wort
DRDO, New
Delhi
15 Lakhs Nov 2008 for 3yrs
Place : JUIT WAKNAGHAT Signature of Investigator
Date : December 14, 2011